Recipharm: 'Client investment gives us competitive edge in CDMO space'

Recipharm: 'Client investment gives us competitive edge in CDMO space'

Parallel deals to invest in Isofol Medical and manufacture the alternative chemotherapy agent Modufolin on its behalf are evidence of Recipharm’s ambitious growth strategy, the CDMO says.

Isofol Medical is a Gothenburg, Sweden-based company which is developing Modufolin, a folate-based biomodulator used in combination with high-toxicity chemotherapeutic drugs. Today the firm announced Recipharm has been awarded a contract to lyophilise and fill/finish the product for upcoming Phase III trials and an exclusive agreement for future commercial manufacture.

Alongside the deal, Recipharm has - through its investor subsidiary Recipharm Venture Fund - invested SEK 8m ($1.2m) into Isofol as part of a strategy that EVP of Development & Technology Carl-Johan Spak said gave Recipharm “a competitive advantage” over rivals in the CDMO space

“A combination of customer collaboration and an investment is a still a small part of our business but in some cases we believe it presents an interesting opportunity,” he told Outsourcing-Pharma.com. “There are not so many companies operating in our space who actually have the financial resources to do this and we therefore believe it gives us a competitive advantage.”

This strategy is not new, Spak said, as Recipharm previously owned shares in French drug delivery firm Crossject, while simultaneously handling its aseptic filling. Furthermore it is not the main driver for Recipharm going forward.

“I am sure that the main growth will come from winning new contracts both in development and manufacturing business through offering our first class services. However, it is a useful complement.”

The investment comes a week after the firm announced it was buying the Milan, Italy-based manufacturer Corvette Pharmaceutical Services Group. Recipharm has been on a spending spree over the past few years and previously told this publication the decision to go public in June was driven by the desire to participate in the consolidation affecting the industry.

Spak confirmed Recipharm’s aim: “We have very ambitious growth targets and it is likely that both new acquisitions and investments will come.”

Modufolin

Until now clinical trial supplies have been supplied by a smaller CMO, Isofol’s Managing Director Anders Rabbe told Outsourcing-Pharma.com.

Modufolin is the key active metabolite of all clinically used folate-based drugs today - including Leucovorin and Levoleucovorin – which are used in order to reduce the damaging effect of chemotherapy agents on healthy cells.

“The idea is to give the active metabolite [Modufolin] directly to patients, as some patients cannot metabolise the current products available,” he said. Furthermore, “with certain treatments Modufolin will strengthen healthy cells while also increasing the potency of the chemotherapeutic agent.”

The API for Modufolin is made by Merck KGaA, and in June 2013 Isofol signed an exclusive license agreement with the German Pharma Giant for the use of the product in cancer treatment.

Related News

Patheon: Expediting supply of Ph I trial drugs can cut pharma costs

Patheon: Expediting supply of Ph I trial drugs can cut pharma costs

Recipharm buys in Portiugal

Recipharm eyes Portugal and opthalmics with SEK1bn Lusomedicamenta buy

Recipharm is buying Flamel's manufacturing facilitynear Bordeaux, France

Recipharm adds French plant and drug delivery tech in strategic deal with Flamel

Recipharm's facility in Strängnäs, Sweden could be shuttered following Meda pull out

Meda cuts Recipharm contract: Swedish plant and jobs under threat

Adroit collaboration: Recipharm teams with solid state formulation firm

Adroit collaboration: Recipharm teams with solid state formulation firm

Recipharm invests in metal-linked API delivery tech in Synthonics deal

Recipharm invests in metal-linked API delivery tech in Synthonics deal

Recipharm in talks to make LIDDS' prostate cancer candidate

Recipharm in talks to make LIDDS' prostate cancer drug-device candidate

Recipharm to buy Milan, Italy-based Corvette

Recipharm to buy Corvette to drive Italian growth and boost freeze drying clout

IPO positions Recipharm as mid-tier CMO with plans to grow

IPO positions Recipharm as mid-tier CMO with plans to grow through takeovers

Recipharm teams with Ph I trials firm

Recipharm teams with Ph I trials firm

Recipharm outlines bluesky acquisition plan post IPO

Public Recipharm plans acquisitions in consolidating CMO sector

Recipharm confirms IPO plan

Recipharm confirms plans to list on OMX

Recipharm cites sales and earnings hike in acquisition plan

Recipharm cites sales and earnings hike in acquisition plan

Recipharm invests €32m in German facility

Recipharm to add lyophilisation capacity with €32m injection

Related Products

See more related products